Drug · CHEMBL354541
LOMITAPIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LOMITAPIDE. Drugs and targets, record CHEMBL354541. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL354541
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 5 diseases, from ATC and EMA Human Drugs
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| MTTP | Microsomal triglyceride transfer protein | Microsomal triglyceride transfer protein inhibitor | INHIBITOR | https://conductscience.org/library/genes/4547 |
| P4HB | Microsomal triglyceride transfer protein | Microsomal triglyceride transfer protein inhibitor | INHIBITOR | https://conductscience.org/library/genes/5034 |
Source ChEMBL
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| familial hypercholesterolemia | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005439 |
| homozygous familial hypercholesterolemia | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0018328 |
| Hypercholesterolemia | Approval | EMA Human Drugs | 3 | 2 | https://conductscience.org/library/drugs?q=HP_0003124 |
| atherosclerosis | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005311 |
| cardiovascular disorder | Approval | ATC | 1 | 0 | https://conductscience.org/library/drugs?q=MONDO_0004995 |
Source Open Targets
Trials15
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00474240 | AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia | Phase 2 | 157 | 2013-02-21 | AEGR-733 | Its name | ClinicalTrials.gov |
| NCT00359281 | Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents | Phase 2 | 125 | 2014-03-04 | AEGR-733 | Its name | ClinicalTrials.gov |
| NCT01760187 | Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C | Phase 1 | 72 | 2018-11-20 | lomitapide | Its name | ClinicalTrials.gov |
| NCT04681170 | Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) | Phase 3 | 46 | 2025-08-27 | lomitapide | Its name | ClinicalTrials.gov |
| NCT02044419 | A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled | Phase 1 | 32 | 2018-02-13 | lomitapide | Its name | ClinicalTrials.gov |
| NCT02080455 | Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects. | Phase 1 | 32 | 2020-03-10 | lomitapide | Its name | ClinicalTrials.gov |
| NCT02080468 | Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects | Phase 1 | 32 | 2019-03-11 | lomitapide | Its name | ClinicalTrials.gov |
| NCT00943306 | Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia | Phase 3 | 19 | 2018-05-11 | lomitapide | Its name | ClinicalTrials.gov |
| NCT01915771 | Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects | Phase 1 | 15 | 2020-03-11 | lomitapide | Its name | ClinicalTrials.gov |
| NCT02173158 | Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy | Phase 3 | 9 | 2018-10-10 | lomitapide | Its name | ClinicalTrials.gov |
1 to 10 of 15
See all 15 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Age 5-10 Years vs Age 11-17 Years: deaths from any cause | 1 of 20 | 1 of 23 | 43 | NCT04681170 | Trial comparisons |
| Age 5-10 Years vs Age 11-17 Years: serious adverse events | 4 of 20 | 7 of 23 | 43 | NCT04681170 | Trial comparisons |
| Lomitapide & Atorvastatin - Taken Together vs Lomitapide & Atorvastatin - Approx. 12 Hours Between: deaths from any cause | 0 of 16 | 0 of 16 | 32 | NCT02080455 | Trial comparisons |
| Lomitapide & Atorvastatin - Taken Together vs Lomitapide & Atorvastatin - Approx. 12 Hours Between: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT02080455 | Trial comparisons |
| Lomitapide & EE/Norgestimate - Taken Together vs Lomitapide & EE/Norgestimate - Taken 12 Hours Apart: deaths from any cause | 0 of 16 | 0 of 16 | 32 | NCT02080468 | Trial comparisons |
| Lomitapide & EE/Norgestimate - Taken Together vs Lomitapide & EE/Norgestimate - Taken 12 Hours Apart: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT02080468 | Trial comparisons |
| Period 1 vs Period 2: deaths from any cause | 0 of 15 | 0 of 13 | 28 | NCT01915771 | Trial comparisons |
| Period 1 vs Period 2: serious adverse events | 0 of 15 | 0 of 13 | 28 | NCT01915771 | Trial comparisons |
| Efficacy Phase vs Safety Phase: deaths from any cause | 0 of 9 | 0 of 8 | 17 | NCT02173158 | Trial comparisons |
| Efficacy Phase vs Safety Phase: serious adverse events | 0 of 9 | 1 of 8 | 17 | NCT02173158 | Trial comparisons |
Papers from its trials5
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL354541
GET https://conductscience.org/api/drugs/v1/CHEMBL354541/targets